Akebia Therapeutics Inc  

(Public, NASDAQ:AKBA)   Watch this stock  
Find more results for Teresa Rice´┐Ż
9.01
-0.17 (-1.85%)
After Hours: 9.01 0.00 (0.00%)
Jul 28, 4:00PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.91 - 9.18
52 week 5.91 - 14.20
Open 9.17
Vol / Avg. 131,794.00/261,446.00
Mkt cap 360.63M
P/E     -
Div/yield     -
EPS -2.43
Shares 37.98M
Beta     -
Inst. own 59%
Aug 9, 2016
Q2 2016 Akebia Therapeutics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jul 12, 2016
Akebia Therapeutics Inc at Cantor Fitzgerald Healthcare Conference - Webcast
Jun 16, 2016
Akebia Therapeutics Inc Annual Shareholders Meeting
Jun 9, 2016
Akebia Therapeutics Inc Annual Shareholders Meeting (Estimated)
May 23, 2016
Akebia Therapeutics Inc at UBS Global Healthcare Conference
May 5, 2016
Q1 2016 Akebia Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -56.80% -47.82%
Return on average equity -69.27% -51.66%
Employees 63 -
CDP Score - -

Address

245 1st St Ste 1100
CAMBRIDGE, MA 02142-1292
United States - Map
+1-617-8712098 (Phone)
+1-617-8712099 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutics based on hypoxia inducible factor (HIF) biology, and the commercialization of these products for patients with serious medical needs. The Company's segment is the business of developing and commercializing proprietary therapeutics based on HIF biology. The Company is involved in developing its lead product candidate, vadadustat, as an oral therapy for the treatment of anemia in chronic kidney disease (CKD) subjects not on dialysis and in subjects on dialysis. Its other clinical candidate, AKB-6899, is designed as a small molecule HIF prolyl-hydroxylase (HIF-PH) inhibitor with therapeutic benefit in oncology and ophthalmology. The Company is engaged in conducting approximately two global Phase III studies for the treatment of anemia in non-dialysis dependent patients, and over two Phase III studies for the treatment of anemia in dialysis-dependent CKD patients.

Officers and directors

John M. Rice Ph.D. Chairman of the Board
Bio & Compensation  - Reuters
John P Butler President, Chief Executive Officer
Age: 50
Bio & Compensation  - Reuters
Jason A Amello Chief Financial Officer, Senior Vice President, Treasurer
Bio & Compensation  - Reuters
Teresa Compton Senior Vice President, Chief Scientific Officer
Bio & Compensation  - Reuters
Bradley J Maroni Senior Vice President, Chief Medical Officer
Bio & Compensation  - Reuters
Nicole R. Hadas Vice President, General Counsel, Secretary
Bio & Compensation  - Reuters
Tamara Dillon Vice President - Human Resources
Bio & Compensation  - Reuters
Ed Joyce Vice President - Investor Relations and Corporate Communications
Bio & Compensation  - Reuters
Mark De Rosch Ph.D. Vice President - Regulatory Affairs
Bio & Compensation  - Reuters
Ramin Farzaneh-Far M.D. Vice President - Medical Research
Bio & Compensation  - Reuters